Clinical Trial Update: Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating VSN16R for spasticity in people with multiple sclerosis has completed. The sponsor is Canbex Therapeutics Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• VSN16R

Snippet

Sponsor: Canbex Therapeutics Ltd | Conditions: Spasticity in People With Multiple Sclerosis | Phase 2 | Status: COMPLETED